JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB269619

Human BCAM knockout A-431 cell line

Human BCAM knockout A-431 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

BCAM KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 100%. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

別名を表示する

Antigen identified by monoclonal antibody F8, Auberger B antigen, B cell adhesion molecule, B-CAM cell surface glycoprotein, BCAM_HUMAN, Basal cell adhesion molecule, Basal cell adhesion molecule (Lu and Au blood groups), Basal cell adhesion molecule (Lutheran blood group), Basal cell adhesion molecule Lu and Au blood groups, Basal cell adhesion molecule Lutheran blood group, CD239, CD239 antigen, F8/G253 antigen, Glycoprotein 95kDa, LU, Lutheran, Lutheran antigen, Lutheran blood group (Auberger b antigen included), Lutheran blood group Auberger b antigen included, Lutheran blood group glycoprotein, MSK19

1 Images
Next Generation Sequencing - Human BCAM knockout A-431 cell line (AB269619)
  • NGS

Supplier Data

Next Generation Sequencing - Human BCAM knockout A-431 cell line (AB269619)

Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift : 100%

Key facts

細胞タイプ

A-431

生物種

Human

組織

Skin

製品の状態

Liquid

form

ノックアウト検証方法

Next Generation Sequencing

ノックアウト変異

Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 100%

疾病

Epidermoid Carcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

製品の詳細

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

製品内容

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab269619-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"Human BCAM knockout A-431 cell line kit component", "number":"AB269619-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab269619-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"Human wild-type A-431 cell line kit component", "number":"AB269619-CMP02", "productcode":"" }, { "size":"1 x 1000000 Cells/vial", "name":"Human BCAM knockout A-431 cell line kit component", "number":"AB269619-CMP01", "productcode":"" } ] } } }

出荷温度及び保存条件

遺伝子名
BCAM
遺伝子編集のタイプ
Knockout
遺伝子編集の方法
CRISPR technology
ノックアウト検証方法
Next Generation Sequencing
出荷温度
Dry Ice
短期保存期間
1-2 weeks
短期保存温度
-196°C|-80°C
長期保存温度
-196°C

取り扱い方法

初回取り扱いガイドライン

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

継代培養ガイドライン
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
培養培地

DMEM (High Glucose) + 10% FBS

凍結保存培地

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

CD239 also known as basal cell adhesion molecule (BCAM) is an integral protein with a mass of about 60 kDa. This protein is primarily expressed in endothelial cells red blood cells and various epithelial tissues. BCAM plays a significant role in cell adhesion acting as a receptor for the extracellular matrix component laminin specifically laminin-511/521. It helps cells attach an essential role for maintaining tissue integrity and cellular communication.
Biological function summary

BCAM influences processes related to cell adhesion and motility. Although not explicitly part of a large complex it interacts closely with the cytoskeleton and mediators of signal transduction. Functions of BCAM involve linking extracellular matrix signals to the intracellular environment impacting cell movement and stabilization within tissues. It also modulates cellular responses to external mechanical stresses playing essential roles in maintaining normal cell function.

Pathways

BCAM is involved in several critical signaling processes including integrin-mediated adhesion and the MAPK/ERK pathway. How BCAM affects these pathways is through its interaction with integrins and elements related to cellular migration and proliferation. Within these pathways related proteins like laminins and other integrin subunits contribute to its adhesion properties and signaling functions enabling coordinated cellular responses to environmental cues.

BCAM is notably associated with sickle cell disease and certain cancers. In sickle cell disease the altered expression or function of BCAM on red blood cells causes abnormal adhesion to the endothelium leading to vaso-occlusion. This adhesion is often exacerbated by interactions with other proteins like L-selectin. In cancer BCAM overexpression correlates with increased tumor cell migration and invasion influencing metastasis and patient prognosis. These associations highlight BCAM's critical role in disease pathology and potential as a therapeutic target.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

製品プロトコール

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com